Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Lactobacillus GG (LGG) in Children With Abdominal Pain (LGGDAR)

This study has been completed.
Clinica PEdiatrica Ospedale San Paolo Bari Italy
Information provided by:
University of Bari Identifier:
First received: April 2, 2009
Last updated: January 31, 2011
Last verified: April 2009
Probiotics play an important role in preventing overgrowth of potentially pathogenic bacteria and maintaining the integrity of the gut mucosal barrier. The beneficial effects of probiotics have been previously studied in adult patients with IBS. Even though most of the studies demonstrate efficacy, other studies do not support these observations. Few studies addresses the efficacy of probiotics in children with IBS. The goal of the present study was to determine whether oral administration of the probiotic Lactobacillus GG under randomized, double-blind, placebo-controlled conditions would improve symptoms of children with abdominal pain.

Condition Intervention
Functional Abdominal Pain
Dietary Supplement: Lactobacillus GG (probiotic )
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Use of Lactobacillus gg in Functional Abdominal Pain in Children: a Double-blind Randomized Control Trial

Resource links provided by NLM:

Further study details as provided by University of Bari:

Primary Outcome Measures:
  • The primary outcome measure was defined as reduction of pain (both number of episodes and intensity) at the end of the intervention. [ Time Frame: 12 weeks and 20 weeks ]

Enrollment: 140
Study Start Date: December 2004
Study Completion Date: August 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
Dietary Supplement: Placebo
placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
Active Comparator: Probiotic
LGG capsules: each cp containing 3 × 109 colony forming units, CFU
Dietary Supplement: Lactobacillus GG (probiotic )
LGG capsules: each cp containing 3 × 109 colony forming units, CFU


Ages Eligible for Study:   4 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients were considered for study inclusion, if they were 4 - 12 years of age and had if they had a pain history of at least 12 weeks (which need not be consecutive) in the preceding 12 months suggestive for IBS or FAP with no structural or metabolic abnormalities to explain the symptoms and according to the Rome II diagnostic criteria valid at the time of the design of the study.
  • IBS was diagnosed in presence of an abdominal discomfort or pain with at least two of three features:

    • relieved with defecation
    • onset associated with a change in stool frequency
    • onset associated with a change in the form (appearance) of the stool.
  • FAP was diagnosed in presence of symptoms of
  • Continuous (nearly continuous) abdominal pain
  • No or only occasional relation of pain with physiological events (e.g. eating, menses)
  • Some loss of daily functioning
  • The pain is not feigned (e.g. malingering)
  • The patient has insufficient criteria for other functional gastrointestinal disorders that would explain the abdominal pain.

Exclusion Criteria:

  • Known concomitant psychiatric, neurological, metabolic, hepatic, renal, infectious, haematological, cardiovascular and pulmonary disease
  • Treatment with antibiotics/probiotics in the last 2 months
  • A pain history suggestive for functional dyspepsia or aerophagia or abdominal migrain
  • Growth failure
  • Gastroparesis
  • Gastrointestinal obstructions/stricture
  • Any disease that may affect bowel motility such as diabetes, connective disease or poorly controlled hypo/hyperthyrodism
  • Previous abdominal surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00876291

Clinica Pediatrica
Bari, Italy, 70100
Sponsors and Collaborators
University of Bari
Clinica PEdiatrica Ospedale San Paolo Bari Italy
Principal Investigator: Ruggiero Francavilla, MD PhD University of Bari
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Clinica Pediatrica Identifier: NCT00876291     History of Changes
Other Study ID Numbers: UB2712
Study First Received: April 2, 2009
Last Updated: January 31, 2011

Additional relevant MeSH terms:
Abdominal Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Signs and Symptoms, Digestive processed this record on May 23, 2017